HighTower Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

HighTower Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,939	Closed	-$284K	–	3774
2021 Q4	$284K	Buy	5,939 +45	+0.8%	+$2.01K	﹤0.01%	2508
2021 Q3	$392K	Hold	5,894	–	–	﹤0.01%	2230
2021 Q2	$459K	Hold	5,894	–	–	﹤0.01%	2099
2021 Q1	$557K	Hold	5,894	–	–	﹤0.01%	1916
2020 Q4	$719K	Buy	5,894 +16	+0.3%	+$1.75K	﹤0.01%	1442
2020 Q3	$513K	Hold	5,878	–	–	﹤0.01%	1558
2020 Q2	$380K	Hold	5,878	–	–	﹤0.01%	1600
2020 Q1	$263K	Hold	5,878	–	–	﹤0.01%	1648
2019 Q4	$366K	Buy	5,878 +28	+0.5%	+$1.33K	﹤0.01%	1595
2019 Q3	$220K	Hold	5,850	–	–	﹤0.01%	2007
2019 Q2	$238K	Buy	+5,850	New	+$209K	﹤0.01%	1941

Other funds holding TPTX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

HighTower Advisors's TPTX Position: Q1 2022 in Review

HighTower Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2022, closing a stake of 5,939 shares — an estimated $284K sold.

HighTower Advisors first reported a position in TPTX in Q2 2019 and held it in 11 quarters. The position peaked at $719K in Q4 2020. 155 funds tracked by Wall St. Rank hold TPTX as of Q1 2022.

HighTower Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
HighTower Advisors sold 5,939 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $284K.
HighTower Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
HighTower Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $719K in Q4 2020.
155 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2022.

Based on HighTower Advisors's 13F filing for Q1 2022, filed 12 May 2022.